1. Home
  2. RYTM vs BLCO Comparison

RYTM vs BLCO Comparison

Compare RYTM & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$93.06

Market Cap

6.4B

Sector

Health Care

ML Signal

N/A

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

N/A

Current Price

$17.05

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RYTM
BLCO
Founded
2008
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
6.0B
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
RYTM
BLCO
Price
$93.06
$17.05
Analyst Decision
Strong Buy
Buy
Analyst Count
14
12
Target Price
$129.43
$18.55
AVG Volume (30 Days)
739.0K
454.5K
Earning Date
01-01-0001
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
28.34
N/A
EPS
N/A
N/A
Revenue
N/A
$5,101,000,000.00
Revenue This Year
$58.38
$8.61
Revenue Next Year
$83.95
$5.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.47
52 Week Low
$45.91
$10.45
52 Week High
$122.20
$18.92

Technical Indicators

Market Signals
Indicator
RYTM
BLCO
Relative Strength Index (RSI) 40.55 42.24
Support Level $83.98 $16.35
Resistance Level $96.92 $17.44
Average True Range (ATR) 4.81 0.58
MACD -0.45 -0.13
Stochastic Oscillator 31.11 30.77

Price Performance

Historical Comparison
RYTM
BLCO

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: